Navigation Links
Over 2,500 Cases Now Filed in Federal Actos Lawsuit Litigation; Case Management Conference Scheduled to Take Place on Thursday
Date:10/23/2013

New York, NY (PRWEB) October 23, 2013

More than 2,500 Actos lawsuit (http://www.consumerinjurylawyers.com/actos/Actos-Lawsuit.html) claims alleging bladder cancer are now pending in a federal multidistrict litigation established in the U.S. District Court, Western District of Louisiana, Bernstein Liebhard LLP reports.

According to a case list update issued October 17th by the U.S. Judicial Panel on Multidistrict Litigation (JPML), the number of lawsuits filed in the proceeding has reached 2,587. Plaintiffs involved in these cases similarly allege that long-term use of the diabetes medication, manufactured by Takeda Pharmaceuticals, can cause bladder cancer. The next Case Management Conference in the federal Actos lawsuit litigation is scheduled to take place on Thursday, October 24th 2013 at 10:30 a.m. (In re: Actos Product Liability Litigation, MDL No. 2299)

“We are not at all surprised to see the number of Actos lawsuits grow in the federal proceeding, as our Firm regularly hears from diabetics who were diagnosed with bladder cancer after long-term use of the medication,” says Bernstein Liebhard LLP, a nationwide law firm representing individuals harmed by defective drugs and medical devices. Call the Firm’s toll-free number today to receive a free and confidential case evaluation of your potential Actos lawsuit.

Actos Lawsuits
Actos lawsuits currently pending in the Western District of Louisiana were filed after a June 2011 alert from the U.S. Food and Drug Administration (FDA) warned about the drug’s association with bladder cancer. Specifically, Takeda Pharmaceuticals was ordered at that time to adjust its Actos labeling to include its potential to cause bladder cancer in diabetics who took the medication for 12 months or more.

Court records indicate that the federal Actos proceeding’s first trial is scheduled to begin in January. This is the first of more than 2,500 cases to head to trial over the diabetes drug, after being brought by plaintiffs who similarly allege that Takeda failed to adequately warn diabetics about the potential for its product to cause bladder cancer prior to the FDA warning in June 2011.

Before then, the company concealed knowledge of this risk, according to lawsuits.
Although federal Actos trials are just beginning, two cases involving the diabetes drug have already gone to trial at the state court level. In September 2013, the family of a man who died of bladder cancer after taking Actos for a long period of time was awarded $1.7 million by a jury in Maryland State Court. Soon after the verdict was reached, however, it was tossed by the judge who found that the patient had smoked for several decades prior to his death, which may have partially contributed to his bladder cancer. (An v. Nieberlein, 24-C12003565, Circuit Court for the City of Baltimore, State of Maryland)

A decision to rule in favor of the plaintiff in a state court-filed Actos lawsuit was set aside earlier this year in Los Angeles Superior Court after a jury awarded $6.5 to an individual who was diagnosed with bladder cancer after taking Actos for four years. This verdict was then set aside by the judge overseeing the case; a decision the plaintiff is now appealing. (Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court)

Individuals who took the diabetes drug, Actos, and were diagnosed with bladder cancer after long-term use of the medication may be entitled to compensation for damages related to their alleged suffering. Learn more about the process of filing an Actos lawsuit against Takeda Pharmaceuticals by visiting Bernstein Liebhard LLP’s website. You may also contact the firm directly at 800-511-5092 today.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

###

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.consumerinjurylawyers.com

Read the full story at http://www.prweb.com/releases/Actos-lawsuit/Actos-lawyer/prweb11262571.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. California Facial Plastic Surgeon Recently Reported Performing Over 2,500 Facelifts Using His Innovative Technique
2. Actos Bladder Cancer Lawsuits Help: Resource4thePeople Reports Number of Consolidated Federal Cases Climbs to over 2,500
3. Screening programs detect cases of undiagnosed rheumatic heart disease in low-resource countries
4. Pneumococcal disease: More cases but fewer deaths
5. Asthma Cases Continue to Rise in U.S., Affecting Millions
6. As Obesity Rates Rise, Cases of Kidney Stones Double: Study
7. Community-acquired MRSA cases on the rise in New York City, study suggests
8. New treatment protocol extends survival in some cases of once inoperable pancreatic cancer
9. Hospitals in recession-hit areas see uptick in serious cases of child physical abuse
10. Whooping Cough Cases Reaching Record Highs: CDC
11. 1 in 20 Cases of Melanoma Linked to Tanning Beds: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... ... On Tuesday, April 26, 2016 members of the HomeTown Health network, a ... Deal on SB 258, the “Rural Health Care Relief” Bill. , The bill, which ... to individuals and corporations which donate directly to a “rural hospital” in Georgia, and ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White House ... their loans, more information about their loan terms and accounts, and more protections ... debt, including federal and private loans, has reached $1.3 trillion, with 43 million ...
(Date:4/29/2016)... ... April 29, 2016 , ... A ... born with severe congenital diaphragmatic hernia have better survival rates if surgery is ... hernia (CDH)—a condition where the diaphragm fails to form completely, letting abdominal organs ...
(Date:4/29/2016)... ... 2016 , ... Mobility Designed is redefining mobility with their patent pending ... Crutch evenly distributes body weight from the elbow to the forearm. In consumer ... than with other crutches. , Co-founders Max and Liliana Younger were inspired to design ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type of skin ... blame for the majority of skin cancer deaths. More than 10,000 people are expected to ... at diagnosis is 62, it is the one of the most commonly diagnosed cancers in ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of oral drug ... the upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... in New York . Nadav Kidron ... the conference. Presentation Details:   ...
(Date:4/28/2016)... New market research titled ... report that provides an overview of the Osteoarthritis,s ... identifying new targets and MOAs to produce first-in-class ... in this H1 2016 Osteoarthritis Pipeline report include ... Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, Inc., ...
(Date:4/27/2016)... , April 27, 2016   ... 42% Growth in Recurring Consumable Sales  Clinical ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of ... its sales for the first quarter ended March 31, ... the execution of its commercial strategy. First ...
Breaking Medicine Technology: